Compare Docusign Inc (DOCU) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Merck & Co., Inc. — how do they compare? Docusign Inc trades at $71.6 (market cap $13.35B), while Merck & Co., Inc. trades at $144.68 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 26.3× Docusign Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Docusign Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and Merck & Co., Inc. for 98 Days on average.
| DOCU | MRK | |
|---|---|---|
Market Cap | $13.35B | $351.28B |
Volume | 3,158,858 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $73.14 | $156.43 |
52-Week Low | $41.75 | $82.49 |
Typical Hold Time | 71 Days | 98 Days |
Enterprise Value | $12.76B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $68.90, up 1.0% on the day, with a bullish technical signal from moving averages and consistent earnings beats in recent quarters. Revenue growth has accelerated to $2.98 billion in 2025, with net income surging to $1.07 billion. The company maintains strong profitability metrics, including a 79.49% gross margin and 17.8% ROE, while recent news highlights AI integration in contract processing and leadership in workflow software.
The outlook is supported by solid fundamentals and positive analyst sentiment, though valuation multiples like a P/E of 43.55 suggest premium pricing. Key risks include market saturation in e-signatures and insider selling activity. The consensus price target of $68.75 aligns closely with the current price, indicating a neutral near-term view with long-term growth potential from AI adoption.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
